You are here

Article info

Article menu

Download PDFPDF

XML
Epidemiology
Original research
Second-generation antipsychotics and the risk of chronic kidney disease: a population-based case-control study

Authors

  • Mikkel Højlund Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark Department of Psychiatry Aabenraa, Mental Health Services in the Region of Southern Denmark, Aabenraa, Denmark PubMed articlesGoogle scholar articles
  • Lars Christian Lund Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark PubMed articlesGoogle scholar articles
  • Jonas Leander Emming Herping Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark PubMed articlesGoogle scholar articles
  • Maija Bruun Haastrup Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark PubMed articlesGoogle scholar articles
  • Per Damkier Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark Clinical Biochemistry, Department of Clinical Research, University of Southern Denmark, Odense, Denmark PubMed articlesGoogle scholar articles
  • Daniel Pilsgaard Henriksen Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark PubMed articlesGoogle scholar articles
  1. Correspondence to Mikkel Højlund; mhoejlund{at}health.sdu.dk
View Full Text

Citation

Højlund M, Lund LC, Herping JLE, et al
Second-generation antipsychotics and the risk of chronic kidney disease: a population-based case-control study
BMJ Open 2020;10:e038247. doi: 10.1136/bmjopen-2020-038247

Publication history

  • Received March 4, 2020
  • Revised July 4, 2020
  • Accepted July 7, 2020
  • First published August 11, 2020.
Online issue publication 
July 10, 2023
Previous versions
Review history

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.